Mankind Pharma

Corporate brand

Mankind Pharma is an Indian multinational pharmaceutical and healthcare company focused on affordable prescription medicines, consumer healthcare, diagnostics, and selected biotech and specialty products.

Last updated November 4, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Mankind Pharma Limited is an Indian pharmaceutical and healthcare company headquartered in Okhla Phase III, New Delhi. Founded by brothers Ramesh C. Juneja and Rajeev Juneja, the company was incorporated in 1991 and began active commercial operations in 1995. It developed from a small, India-focused medicines business into a broad healthcare platform spanning prescription pharmaceuticals, over-the-counter products, consumer healthcare, diagnostics, active pharmaceutical ingredients, veterinary products, pet care, agritech, and specialty biopharmaceuticals. The company’s early commercial model was built around affordability, mass-market distribution, and penetration of price-sensitive segments, especially in rural and semi-urban India. Its first products included the antibacterial brand Zenflox and the prescription antibiotic Moxikind-CV. These products were positioned at prices below many established competitors, helping Mankind establish a reputation for accessible medicines. Rather than initially competing only in premium urban categories, the company used a large field-force and distribution network to reach doctors, pharmacists, and patients across a wide geographic base. Mankind entered consumer healthcare in 2007, initially emphasizing sexual and reproductive health. This expansion created several of the company’s most recognizable brands. Manforce became a major condom franchise; Prega News developed into a leading pregnancy-detection and pregnancy-care brand; and Unwanted-72 became a prominent emergency-contraception product. The company subsequently broadened its consumer portfolio with brands such as Gas-O-Fast, AcneStar, HealthOK, and related wellness and personal-care products. Its consumer businesses rely heavily on mass media, digital advertising, celebrity endorsements, regional marketing, chemist relationships, e-commerce, and increasingly localized campaigns. Mankind has also expanded through acquisitions and internal diversification. The 2007 acquisition of Magnet Labs supported entry into antipsychotic medicines, while the 2010 acquisition of Longifene added a pediatric appetite-stimulant brand formerly associated with UCB. In 2017, the company established Pathkind Labs to build a diagnostics business. It later entered agritech and pet care, reflecting an effort to use its commercial infrastructure beyond conventional human pharmaceuticals. Research and product development have become increasingly important to the company’s positioning. In 2019, Mankind launched Dydroboon, a dydrogesterone product used in areas including infertility treatment and high-risk pregnancy care. The company has also expanded into chronic therapies, women’s health, respiratory care, dermatology, cardiovascular medicine, gastrointestinal products, diabetes, neurology, and other prescription categories. Its manufacturing and research infrastructure includes numerous Indian production facilities and dedicated R&D centers covering formulation development, analytical work, APIs, biotechnology, and related capabilities. Mankind accelerated its portfolio expansion in 2022. It acquired domestic formulation brands from Panacea Biotec Pharma in India and Nepal, purchased selected respiratory and infant-care brands from Dr. Reddy’s Laboratories, and acquired a majority stake in Ayurvedic and herbal-products company Upakarma Ayurveda. These transactions strengthened the company’s presence in established therapeutic and consumer categories while adding complementary distribution opportunities. In April 2023, Mankind completed an initial public offering consisting primarily of an offer for sale by existing shareholders. Its equity shares began trading on the National Stock Exchange of India and BSE in May 2023 under the symbol MANKIND. The listing increased the company’s public-market profile while leaving the founding family and other long-term shareholders central to its ownership and governance structure. The company made its largest strategic move to date in 2024 by agreeing to acquire and subsequently completing the acquisition of 100 percent of Bharat Serums and Vaccines Limited from Advent International. The transaction, completed in October 2024, substantially expanded Mankind’s exposure to women’s health, fertility, critical care, immunoglobulins, biologics, and complex drug-delivery technologies. It also added more than 2,500 employees and strengthened Mankind’s ability to participate in higher-barrier pharmaceutical and biotechnology markets. Mankind remains primarily an Indian business, although it sells products internationally and is developing broader capabilities in regulated and emerging markets. Its current identity combines a value-oriented Indian generics franchise with consumer brands, diagnostics, specialty medicines, and acquired biopharmaceutical capabilities. The company describes its strategic priorities in terms of quality, affordability, accessibility, innovation, manufacturing scale, and deeper participation in women’s health and other specialized therapeutic areas.

History

Mankind Pharma was incorporated in 1991 by brothers Ramesh C. Juneja and Rajeev Juneja and began active operations in 1995. The founders started with a relatively small amount of capital and a compact workforce, initially concentrating on the Indian market and launching products in two states. The company’s early strategy was to address price-sensitive demand through affordable branded generics and a broad sales and distribution network. Its first phase of growth centered on prescription medicines. Products such as Zenflox and Moxikind-CV were introduced as lower-priced alternatives in antibiotic and antibacterial categories. This approach was particularly relevant in rural and semi-urban markets, where treatment affordability and medicine availability were major commercial considerations. Mankind’s growth depended not only on manufacturing and product selection but also on its ability to place medical representatives and distribution partners close to doctors, pharmacies, and patients. In 2007, the company entered the over-the-counter segment. Sexual healthcare became an early focus, providing the basis for the later expansion of Manforce and other consumer brands. The same year, Mankind acquired Magnet Labs Private Limited, supporting entry into antipsychotic medicines. In January 2010, it acquired Longifene, a pediatric appetite-stimulant brand previously associated with UCB. These moves showed an emerging willingness to combine organic product development with acquisitions of established brands. During the 2010s, Mankind built a more diversified therapeutic platform. Its prescription portfolio expanded into gastrointestinal, cardiovascular, dermatology, diabetes, neurology, respiratory, women’s health, and other categories. At the same time, its consumer healthcare business developed into a major source of brand visibility. Manforce condoms, Prega News pregnancy-test products, and Unwanted emergency contraception became some of the company’s most recognizable offerings. Brands such as Gas-O-Fast, AcneStar, and HealthOK later broadened its presence in wellness, digestive care, dermatology, and personal healthcare. Mankind also invested in adjacent healthcare services. In 2017, it established Pathkind Labs as a diagnostics business, extending its activities beyond medicines into laboratory testing and health screening. The company’s research ambitions became more visible in 2019 when it launched Dydroboon, a dydrogesterone product used in infertility and high-risk pregnancy care. This strengthened Mankind’s position in women’s health and demonstrated its intent to compete in more specialized prescription categories. The company’s manufacturing and R&D capabilities expanded in parallel. By the early 2020s, it operated a large Indian production network covering tablets, capsules, syrups, vials, ampoules, soft and hard gels, eye drops, creams, contraceptives, and other dosage forms. Its R&D infrastructure included dedicated facilities for formulation development, APIs, analytical work, biotechnology, and new drug discovery-related activities. Although exports remained smaller than domestic sales, Mankind developed an international presence in markets across Africa, the Commonwealth of Independent States, Southeast Asia, Nepal, Sri Lanka, and other regions. A significant expansion phase began in 2022. Mankind acquired domestic formulation brands from Panacea Biotec Pharma in India and Nepal. It also acquired selected respiratory and infant-care brands from Dr. Reddy’s Laboratories and purchased a majority stake in Upakarma Ayurveda. In the same period, the company entered agritech and pet care, reflecting a broader consumer and life-sciences strategy rather than a narrow focus on conventional prescription medicines. In April 2023, Mankind launched its initial public offering. The transaction was primarily an offer for sale by existing shareholders rather than a capital-raising issue for the company. The shares were listed on the NSE and BSE in May 2023 under the ticker MANKIND. Public listing increased disclosure requirements and market visibility while the founding family continued to occupy central leadership roles. The most consequential transaction in the company’s history occurred in 2024. Mankind agreed to acquire Bharat Serums and Vaccines from Advent International and completed the acquisition in October of that year. The transaction gave Mankind full ownership of a business with capabilities in women’s health, fertility, critical care, immunoglobulins, recombinant products, niche biologics, and complex drug-delivery systems. More than 2,500 BSV employees joined the combined organization. The acquisition shifted Mankind toward a more balanced mix of high-volume branded generics, consumer products, and higher-barrier specialty pharmaceuticals. Mankind’s current strategy is therefore the result of several overlapping stages: affordable Indian branded generics; consumer-healthcare brand building; expansion into diagnostics and adjacent categories; selective acquisitions; and movement into biologics, fertility, critical care, and other specialized therapies. The company continues to emphasize quality, affordability, accessibility, manufacturing scale, and research-led product development while remaining primarily rooted in the Indian pharmaceutical market.

2024
Agreement to acquire Bharat Serums and Vaccines
[6]Mankind Pharma agreement to acquire Bharat Serums and Vaccinesmankindpharma.com
Mankind announces an agreement to acquire all shares of Bharat Serums and Vaccines from Advent International.
2024
Bharat Serums and Vaccines acquisition completed
[7]Mankind Pharma completion of Bharat Serums and Vaccines acquisitionmankindpharma.com
Mankind completes the acquisition of BSV, adding women’s health, fertility, critical-care, immunoglobulin, and biologics capabilities.
2023
Initial public offering and stock-market listing
[4]Mankind Pharma IPO prospectussebi.gov.in
Mankind completes an IPO and begins trading on the NSE and BSE in May 2023.
2022
Panacea Biotec brand acquisition
[11]Panacea Biotec brand acquisitionbusinesstoday.in
Mankind acquires domestic formulation brands from Panacea Biotec Pharma in India and Nepal.
2022
Diversification into agritech and pet care
[1]Mankind Pharmaen.wikipedia.org
The company enters agritech and pet care while continuing to expand its consumer-healthcare activities.
2019
Dydroboon is launched
[1]Mankind Pharmaen.wikipedia.org
Mankind launches Dydroboon, a dydrogesterone product for infertility and high-risk pregnancy-related care.
2017
Pathkind Labs is established
[1]Mankind Pharmaen.wikipedia.org
Mankind establishes Pathkind Labs to build a diagnostics and laboratory-testing business.
2010
Longifene acquisition
[1]Mankind Pharmaen.wikipedia.org
Mankind acquires Longifene, a pediatric appetite-stimulant brand previously associated with UCB.
2007
Entry into over-the-counter healthcare
[1]Mankind Pharmaen.wikipedia.org
Mankind enters the OTC segment, initially emphasizing sexual-health and consumer products.
2007
Magnet Labs acquisition
[1]Mankind Pharmaen.wikipedia.org
The acquisition of Magnet Labs supports Mankind’s entry into antipsychotic medicines.
1995
Commercial operations begin
[1]Mankind Pharmaen.wikipedia.org
The company begins active operations with a small workforce and initially launches products in two Indian states.
1991
Mankind Pharma is incorporated
[1]Mankind Pharmaen.wikipedia.org
Mankind Pharma is incorporated in India by brothers Ramesh C. Juneja and Rajeev Juneja.

Products and positioning

A broad Indian healthcare company built around affordable, accessible medicines and high-volume distribution, with a strong consumer-healthcare presence and an expanding portfolio in women’s health, fertility, specialty pharmaceuticals, diagnostics, and biologics.

Condoms and sexual wellness
Manforce
Manforce is Mankind Pharma’s flagship condom and sexual-wellness franchise. It includes multiple variants positioned around protection, sensation, fit, endurance, and product experience. The brand became central to Mankind’s OTC strategy and is supported by mass-media, influencer, digital-commerce, and seasonal campaigns. Its marketing has often used direct, humorous, and culturally visible communication to normalize condom conversations and connect the product with safer sex and mutual choice.
Pregnancy detection and pregnancy care
Prega News
Prega News is a pregnancy-detection brand that has expanded into a wider pregnancy-care platform. Its core offering is a home pregnancy test, while related extensions and communications address fertility, pregnancy information, emotional support, and the role of partners and families. The brand uses television, digital media, chemist-shop activation, influencer marketing, and partnerships to reach consumers across urban and rural India.
Emergency contraception
Unwanted-72
Unwanted-72 is Mankind’s emergency-contraception franchise. It is positioned as an accessible, discreet reproductive-health product within the company’s broader women’s-health and sexual-health portfolio. The Unwanted brand family has also included other reproductive-health products, allowing Mankind to cover emergency contraception, pregnancy testing, and related reproductive-care needs through a connected consumer platform.
Digestive and gastrointestinal consumer healthcare
Gas-O-Fast
Gas-O-Fast is a consumer-healthcare franchise focused on digestive discomfort and acidity-related needs. It is sold in convenient formats including sachets and is marketed through broad-reach advertising, sampling, retail activation, and regional campaigns. The product illustrates Mankind’s strategy of building high-recognition OTC brands that can use the company’s extensive chemist, distributor, modern-trade, and e-commerce network.
Dermatology and skincare
AcneStar
AcneStar is Mankind’s dermatology and skincare franchise associated primarily with acne management and related personal-care needs. It sits between prescription-oriented dermatology and consumer skincare, allowing the company to reach both doctor-recommended and self-care audiences. The brand contributes to Mankind’s broader strategy of combining therapeutic credibility with consumer-facing packaging, education, and digital marketing.
Vitamins and nutritional supplements
HealthOK
HealthOK is a consumer-healthcare and nutritional-supplement brand within Mankind’s wellness portfolio. Its products are designed for everyday supplementation and general health support rather than treatment of a single disease. The franchise helps Mankind participate in the expanding vitamins, minerals, supplements, and preventive-wellness market through retail, modern trade, e-commerce, and mass consumer communication.
Neurology and vitamin supplementation
Nurokind
Nurokind is a major prescription brand family associated with vitamin and nerve-health therapies. The range includes multiple formulations and combinations designed for different clinical and supplementation needs. It represents Mankind’s large branded-generic business, in which a recognizable mother brand is extended across strengths, combinations, dosage forms, and physician-led therapeutic uses.
Antibiotics and anti-infectives
Moxikind
Moxikind is one of Mankind Pharma’s early and best-known prescription franchises. The range includes antibiotic products such as Moxikind-CV and related formulations. Its history reflects the company’s original focus on affordable branded generics and price-sensitive treatment markets. The franchise remains part of the company’s anti-infective and prescription-medicine heritage.
Women’s health and fertility · 2019
Dydroboon
Dydroboon is Mankind’s dydrogesterone brand, launched in 2019 for uses including infertility treatment and high-risk pregnancy care. The product strengthened the company’s women’s-health franchise and represented an important move beyond high-volume generics into more specialized reproductive-health therapy. It also created a platform that complemented Mankind’s consumer brands in pregnancy detection and emergency contraception.
Biologics, fertility, women’s health, and critical care
Bharat Serums and Vaccines portfolio
The Bharat Serums and Vaccines portfolio added biologics and other specialized products to Mankind Pharma following the 2024 acquisition. The acquired business covers women’s health, fertility, critical care, immunoglobulins, emergency medicine, recombinant products, niche biologics, and complex drug-delivery systems. Products and technologies associated with the portfolio include fertility and reproductive-health therapies, Anti-D, Foligraf, Thymogam, and antivenom-related capabilities.

Marketing campaigns

2025Prega News Invisible Journey of Fathers
India
Prega News used a Father’s Day film to highlight the physical and emotional support provided by expectant fathers while also drawing attention to the less visible difficulties experienced by pregnant women.
Outcome. The campaign extended Prega News’s brand narrative toward shared parenthood, empathy, and partner support during pregnancy.
Source
2024#CondomNahiManforceBolo
India
Manforce collaborated with Dolly Singh on a digital campaign encouraging consumers to associate the generic word “condom” with the Manforce brand. The campaign used humor, influencers, user-generated content, social media, e-commerce, quick-commerce, and product-placement activity.
Outcome. The year-long campaign was designed to increase brand salience and reinforce Manforce’s claimed leadership in India’s condom segment.
Source
2024Manforce Epic ThinX female-choice campaign
India
Manforce promoted its Epic ThinX condom line through a campaign featuring Radhika Apte that emphasized female participation in condom selection, sexual comfort, protection, and informed choice.
Outcome. The campaign attempted to shift condom communication away from an exclusively male purchasing perspective and toward joint decision-making and women’s sexual-health agency.
Source
2023Prega News chemist and rural-market activation
India
Prega News used celebrity-led video, chemist-shop communication, and localized digital advertising to strengthen its relationship with retail chemists and improve visibility around pregnancy testing and care.
Outcome. The program expanded the brand’s communication from mass advertising toward targeted retail and local digital activation.
Source
2020Real-life support and pandemic initiatives
India
During the COVID-19 period, Mankind used corporate and brand communication to recognize healthcare workers, support frontline personnel, and emphasize social solidarity. The company also used regional influencers and digital channels to maintain communication for brands including Manforce, AcneStar, Gas-O-Fast, and Prega News.
Outcome. The initiatives helped maintain brand visibility while shifting communication toward public support, reassurance, and digital engagement.
Source
2016#YourSecondHome
India
Prega News partnered with SpiceJet on an initiative intended to make air travel more comfortable for pregnant women and to position the brand as a supportive presence during pregnancy rather than only a pregnancy-test provider.
Outcome. The campaign broadened Prega News’s emotional and service-oriented positioning and generated media coverage around pregnancy support.
Source

Brand decisions

2024
Acquire Bharat Serums and VaccinesM&A
Background
Mankind aimed to move further into higher-entry-barrier pharmaceuticals and strengthen its position in women’s health, fertility, critical care, immunoglobulins, and biologics.
Action taken
Mankind agreed to acquire and then completed the purchase of 100 percent of Bharat Serums and Vaccines from Advent International.
Aftermath
The completed transaction added BSV’s specialized product portfolio, R&D platforms, manufacturing capabilities, and more than 2,500 employees to Mankind.
Purchase consideration. Approximate enterprise value of INR 13,630 crore at announcement → Purchase consideration of approximately INR 13,768.22 crore at completion (July to October 2024)
Source
2023
Complete the initial public offeringOther
Background
Mankind sought a public-market listing after years of privately held growth, giving existing shareholders liquidity and creating a listed platform for future expansion.
Action taken
The company launched an IPO consisting primarily of an offer for sale by promoter and investor shareholders, followed by listings on the NSE and BSE.
Aftermath
Mankind became a publicly traded Indian pharmaceutical company, increasing reporting obligations, investor visibility, and access to public-market capital over time.
Offer size. INR 4,326.355 million (2023 IPO)
Source
2022
Acquire Panacea Biotec domestic formulation brandsM&A
Background
Mankind wanted to accelerate prescription-portfolio expansion through established brands and deepen its presence in India and Nepal.
Action taken
Mankind acquired Panacea Biotec Pharma’s domestic formulation brands in India and Nepal.
Aftermath
The acquisition added established products and supported the company’s strategy of combining organic growth with portfolio acquisitions.
Purchase consideration. INR 1,872 crore (2022 transaction announcement)
Source
2022
Acquire selected Dr. Reddy’s consumer and respiratory brandsM&A
Background
Mankind pursued established products that could be integrated into its prescription, respiratory, dermatology, and consumer-healthcare distribution network.
Action taken
The company acquired selected respiratory and infant-care brands from Dr. Reddy’s Laboratories.
Aftermath
The transaction broadened Mankind’s category coverage and added products with existing market recognition.
Source
2019
Launch Dydroboon in women’s healthProduct launch
Background
Mankind identified women’s health, infertility, and pregnancy-related treatment as strategic therapeutic areas with opportunities for branded prescription products.
Action taken
The company launched Dydroboon, a dydrogesterone product for infertility and high-risk pregnancy-related care.
Aftermath
The launch strengthened Mankind’s women’s-health franchise and complemented its consumer reproductive-health brands.
Source
2017
Create a diagnostics platform through Pathkind LabsStrategy
Background
Mankind sought to expand beyond medicines and participate in health testing and laboratory services.
Action taken
The company established Pathkind Labs as a diagnostics and healthcare-testing business.
Aftermath
Pathkind gave Mankind an adjacent healthcare-services platform and broadened its relationship with patients and healthcare providers.
Source
2007
Enter the over-the-counter and sexual-health marketStrategy
Background
Mankind’s initial business was centered on prescription branded generics and price-sensitive medicines. The company identified consumer healthcare, particularly sexual health, as an opportunity to build nationally visible brands and diversify revenue.
Action taken
Mankind entered the OTC segment and developed a consumer portfolio that eventually included Manforce, Prega News, and Unwanted.
Aftermath
The move created some of the company’s most recognizable franchises and gave Mankind a stronger direct-to-consumer marketing identity.
Source

Recent events

2021-07-21
SafeKind launches digital campaign on public toilet hygiene[17]SafeKind推出公共厕所卫生数字营销活动indiantelevision.com
Reported: 2021-07-21
SafeKind launched its first-ever digital campaign highlighting toilet seat sanitiser sprays and hygiene concerns women face when using public washrooms. The campaign was released on digital platforms and the brand's social media handles.
2019-12-05
Mankind Pharma launches generic Dydrogesterone tablets in India[18]Mankind Pharma在印度推出通用名地屈孕酮片business-standard.com
Reported: 2019-12-05
Mankind Pharma said it launched generic Dydrogesterone tablets in India for the treatment of infertility and pregnancy-related complications.

Sources18 sources

Cite this profile: Cite the canonical profile. /brand-wiki/mankind-pharma · Editorial policy · How profiles are compiled